Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: Part II. Autologous Transplantation-Novel Agents and Immunomodulatory Strategies

Biology of Blood and Marrow Transplantation

Volumn 19, Issue 12, 2013, Pages 1661-1669

  Avigan, David ^a   Hari, Parameswaran ^b   Battiwalla, Minoo ^c   Bishop, Michael R ^d   Giralt, Sergio A ^e   Hardy, Nancy M ^f   Kröger, Nicolaus ^g   Wayne, Alan S ^f,h   Hsu, Katharine C ^e  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f NATIONAL CANCER INSTITUTE   (United States)

^g UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^h UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Allogeneic; Autologous; Hematopoietic stem cell transplantation; Multiple myeloma; Relapse

Indexed keywords

ANTINEOPLASTIC AGENT; AT 7519; BORTEZOMIB; BT 062; CARFILZOMIB; CD137 ANTIGEN; CD150 ANTIGEN; CD38 ANTIGEN; CD56 ANTIGEN; CD74 ANTIGEN; DARATUMUMAB; DEXAMETHASONE; ELOTUZUMAB; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; IXAZOMIB; IXAZOMIB CITRATE; LENALIDOMIDE; LORVOTUZUMAB; MILATUZUMAB; MYELOBLASTIN; OPROZOMIB; PANOBINOSTAT; PLACEBO; POMALIDOMIDE; RICOLINOSTAT; RITUXIMAB; SALINOSPORAMIDE A; SAR 650984; SYNDECAN 1; THALIDOMIDE; UNCLASSIFIED DRUG; VORINOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIGEN SPECIFICITY; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER PREVENTION; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER REGISTRY; CANCER REGRESSION; CANCER SURVIVAL; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; EFFECTOR CELL; FLOW CYTOMETRY; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA; LONG TERM SURVIVAL; MINIMAL RESIDUAL DISEASE; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; NATIONAL HEALTH ORGANIZATION; NATURAL KILLER CELL; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RECURRENCE RISK; REGULATORY T LYMPHOCYTE; SALVAGE THERAPY; TUMOR IMMUNITY;

ALLOGENEIC; AUTOLOGOUS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MULTIPLE MYELOMA; RELAPSE;

HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOMODULATION; MULTIPLE MYELOMA; NATIONAL CANCER INSTITUTE (U.S.); NEOPLASM RECURRENCE, LOCAL; TRANSPLANTATION CONDITIONING; TRANSPLANTATION IMMUNOLOGY; TRANSPLANTATION, AUTOLOGOUS; UNITED STATES;

EID: 84887521007     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2013.08.011     Document Type: Article

References (97)

1. Kumar S.K., Rajkumar S.V., Dispenzieri A., et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008, 111:2516-2520.
2. Mahindra A., Laubach J., Raje N., et al. Latest advances and current challenges in the treatment of multiple myeloma. Nat Rev Clin Oncol 2012, 9:135-143.
3. Costa L.J., Zhong X., Zhang M.-J., et al. Trends in utilization and outcomes of autologous hematopoietic cell transplantation (AHCT) in the upfront management of patients with multiple myeloma: A CIBMTR analysis. ASH Annual Meet Abstr 2012, 120:596.
4. Durie B.G., Harousseau J.L., Miguel J.S., et al. International uniform response criteria for multiple myeloma. Leukemia 2006, 20:1467-1473.
5. Bartel T.B., Haessler J., Brown T.L., et al. F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood 2009, 114:2068-2076.
6. Rajkumar S.V., Harousseau J.L., Durie B., et al. Consensus recommendations for the uniform reporting of clinical trials: Report of the International Myeloma Workshop Consensus Panel 1. Blood 2011, 117:4691-4695.
7. Laubach J.P., Mitsiades C.S., Mahindra A., et al. Management of relapsed and relapsed/refractory multiple myeloma. JNatl Compr Canc Netw 2011, 9:1209-1216.
8. Kumar S.K., Therneau T.M., Gertz M.A., et al. Clinical course of patients with relapsed multiple myeloma. Mayo Clin Proc 2004, 79:867-874.
9. Alegre A., Granda A., Martinez-Chamorro C., et al. Different patterns of relapse after autologous peripheral blood stem cell transplantation in multiple myeloma: Clinical results of 280 cases from the Spanish Registry. Haematologica 2002, 87:609-614.
10. Durie B.G., Moreau P., Sonneveld P., et al. Regional differences in the treatment approaches for relapsed multiple myeloma: An IMF study. ASCO Meet Abstr 2012, 30:8095.
11. Garderet L., Iacobelli S., Moreau P., et al. Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: The MMVAR/IFM 2005-04 Randomized Phase III Trial from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. JClin Oncol 2012, 30:2475-2482.
12. Kumar S.K., Lee J.H., Lahuerta J.J., et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study. Leukemia 2012, 26:149-157.
13. Martinez-Lopez J., Blade J., Mateos M.V., et al. Long-term prognostic significance of response in multiple myeloma after stem cell transplantation. Blood 2011, 118:529-534.
14. Barlogie B., Zangari M., Bolejack V., et al. Superior 12-year survival after at least 4-year continuous remission with tandem transplantations for multiple myeloma. Clin Lymph Myel 2006, 6:469-474.
15. Porrata L.F., Gertz M.A., Inwards D.J., et al. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma. Blood 2001, 98:579-585.
16. Gress R.E., Miller J.S., Battiwalla M., et al. Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: Part I. Biology of Relapse after Transplantation. Biol Blood Marrow Transplant 2013, 19:1537-1545.
17. Hiwase D.K., Hiwase S., Bailey M., et al. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma. Biol Blood Marrow Transplant 2008, 14:116-124.
18. Pessoa de Magalhaes R.J., Vidriales M.B., Paiva B., et al. Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry. Haematologica 2012, 98:79-86.
19. Hart A.J., Jagasia M.H., Kim A.S., et al. Minimal residual disease in myeloma: Are we there yet?. Biol Blood Marrow Transplant 2012, 18:1790-1799.
20. Corradini P., Voena C., Tarella C., et al. Molecular and clinical remissions in multiple myeloma: Role of autologous and allogeneic transplantation of hematopoietic cells. JClin Oncol 1999, 17:208-215.
21. Martinelli G., Terragna C., Zamagni E., et al. Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma. JClin Oncol 2000, 18:2273-2281.
22. Corradini P., Cavo M., Lokhorst H., et al. Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma. Blood 2003, 102:1927-1929.
23. Rawstron A.C., Davies F.E., DasGupta R., et al. Flow cytometric disease monitoring in multiple myeloma: The relationship between normal and neoplastic plasma cells predicts outcome after transplantation. Blood 2002, 100:3095-3100.
24. Paiva B., Gutierrez N.C., Rosinol L., et al. High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma. Blood 2012, 119:687-691.
25. Rawstron A.C., Child J.A., de Tute R.M., et al. Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: Impact on outcome in the Medical Research Council Myeloma IX Study. JClin Oncol 2013, 31:2540-2547.
26. Paiva B., Martinez-Lopez J., Vidriales M.B., et al. Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma. JClin Oncol 2011, 29:1627-1633.
27. Egan J.B., Shi C.X., Tembe W., et al. Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. Blood 2012, 120:1060-1066.
28. Keats J.J., Chesi M., Egan J.B., et al. Clonal competition with alternating dominance in multiple myeloma. Blood 2012, 120:1067-1076.
29. Venner C.P., Connors J.M., Sutherland H.J., et al. Novel agents improve survival of transplant patients with multiple myeloma including those with high-risk disease defined by early relapse (<12 months). Leuk Lymph 2011, 52:34-41.
30. Usmani S.Z., Crowley J., Hoering A., et al. Improvement in long-term outcomes with successive total therapy trials for multiple myeloma: Are patients now being cured?. Leukemia 2012, 27:226-232.
31. Michaelis L.C., Saad A., Zhong X., et al. Salvage second hematopoietic cell transplantation in myeloma. Biol Blood Marrow Transplant 2013, 19:760-766.
32. Freytes C.O., Vesole D.H., Zhong X., et al. Second transplants in relapsed multiple myeloma (MM): Autologous (AHCT) versus non-myeloablative/reduced intensity (NST/RIC) allogeneic transplantation (AlloHCT). ASH Annual Meet Abstr 2011, 118:824.
33. Koehne G., Giralt S. Allogeneic hematopoietic stem cell transplantation for multiple myeloma: Curative but not the standard of care. Curr Opin Oncol 2012, 24:720-726.
34. Bruno B., Rotta M., Patriarca F., et al. Acomparison of allografting with autografting for newly diagnosed myeloma. NEngl J Med 2007, 356:1110-1120.
35. Giaccone L., Storer B., Patriarca F., et al. Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma. Blood 2011, 117:6721-6727.
36. Krishnan A., Pasquini M.C., Logan B., et al. Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): A phase 3 biological assignment trial. Lancet Oncol 2011, 12:1195-1203.
37. Gahrton G., Iacobelli S., Bjorkstrand B., et al. Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: Long-term results of the EBMT-NMAM2000 study. Blood 2013, 121:5055-5063.
38. Armeson K.E., Hill E.G., Costa L.J. Tandem autologous vs autologous plus reduced intensity allogeneic transplantation in the upfront management of multiple myeloma: Meta-analysis of trials with biological assignment. Bone Marrow Transplant 2013, 48:562-567.
39. Tricot G., Vesole D.H., Jagannath S., et al. Graft-versus-myeloma effect: Proof of principle. Blood 1996, 87:1196-1198.
40. Zeiser R., Bertz H., Spyridonidis A., et al. Donor lymphocyte infusions for multiple myeloma: Clinical results and novel perspectives. Bone Marrow Transplant 2004, 34:923-928.
41. Kolb H.J., Schattenberg A., Goldman J.M., et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995, 86:2041-2050.
42. Ohminami H., Yasukawa M., Fujita S. HLA class I-restricted lysis of leukemia cells by a CD8(+) cytotoxic T-lymphocyte clone specific for WT1 peptide. Blood 2000, 95:286-293.
43. Gaiger A., Reese V., Disis M.L., Cheever M.A. Immunity to WT1 in the animal model and in patients with acute myeloid leukemia. Blood 2000, 96:1480-1489.
44. Scheibenbogen C., Letsch A., Thiel E., et al. CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia. Blood 2002, 100:2132-2137.
45. Molldrem J., Dermime S., Parker K., et al. Targeted T-cell therapy for human leukemia: Cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells. Blood 1996, 88:2450-2457.
46. Greiner J., Li L., Ringhoffer M., et al. Identification and characterization of epitopes of the receptor for hyaluronic acid-mediated motility (RHAMM/CD168) recognized by CD8+ T cells of HLA-A2-positive patients with acute myeloid leukemia. Blood 2005, 106:938-945.
47. Ochi T., Fujiwara H., Suemori K., et al. Aurora-A kinase: A novel target of cellular immunotherapy for leukemia. Blood 2009, 113:66-74.
48. Rezvani K., Yong A.S., Tawab A., et al. Exvivo characterization of polyclonal memory CD8+ T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia. Blood 2009, 113:2245-2255.
49. Brossart P., Schneider A., Dill P., et al. The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes. Cancer Res 2001, 61:6846-6850.
50. Hundemer M., Schmidt S., Condomines M., et al. Identification of a new HLA-A2-restricted T-cell epitope within HM1.24 as immunotherapy target for multiple myeloma. Exp Hematol 2006, 34:486-496.
51. Lim S.H., Wang Z., Chiriva-Internati M., Xue Y. Sperm protein 17 is a novel cancer-testis antigen in multiple myeloma. Blood 2001, 97:1508-1510.
52. Szmania S., Tricot G., van Rhee F. NY-ESO-1 immunotherapy for multiple myeloma. Leuk Lymph 2006, 47:2037-2048.
53. Atanackovic D., Arfsten J., Cao Y., et al. Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation. Blood 2007, 109:1103-1112.
54. Avigan D. Dendritic cells: Development, function and potential use for cancer immunotherapy. Blood Rev 1999, 13:51-64.
55. Tsuboi A., Oka Y., Kyo T., et al. Long-term WT1 peptide vaccination for patients with acute myeloid leukemia with minimal residual disease. Leukemia 2012, 26:1410-1413.
56. Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer 2012, 12:265-277.
57. Mailander V., Scheibenbogen C., Thiel E., et al. Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity. Leukemia 2004, 18:165-166.
58. Rezvani K., Yong A.S., Mielke S., et al. Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood 2008, 111:236-242.
59. Keilholz U., Letsch A., Busse A., et al. Aclinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. Blood 2009, 113:6541-6548.
60. Schmitt M., Schmitt A., Rojewski M.T., et al. RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses. Blood 2008, 111:1357-1365.
61. Roddie H., Klammer M., Thomas C., et al. Phase I/II study of vaccination with dendritic-like leukaemia cells for the immunotherapy of acute myeloid leukaemia. Br J Haematol 2006, 133:152-157.
62. Li L., Giannopoulos K., Reinhardt P., et al. Immunotherapy for patients with acute myeloid leukemia using autologous dendritic cells generated from leukemic blasts. Int J Oncol 2006, 28:855-861.
63. Ho V.T., Vanneman M., Kim H., et al. Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation. Proc Natl Acad Sci USA 2009, 106:15825-15830.
64. Vasir B., Borges V., Wu Z., et al. Fusion of dendritic cells with multiple myeloma cells results in maturation and enhanced antigen presentation. Br J Haematol 2005, 129:687-700.
65. Rosenblatt J., Wu Z., Vasir B., et al. Generation of tumor-specific T lymphocytes using dendritic cell/tumor fusions and anti-CD3/CD28. JImmunother 2010, 33:155-166.
66. Rosenblatt J., Vasir B., Uhl L., et al. Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma. Blood 2011, 117:393-402.
67. Borrello I., Sotomayor E.M., Rattis F.M., et al. Sustaining the graft-versus-tumor effect through posttransplant immunization with granulocyte-macrophage colony-stimulating factor (GM-CSF)-producing tumor vaccines. Blood 2000, 95:3011-3019.
68. Borrello I.M., Levitsky H.I., Stock W., et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML). Blood 2009, 114:1736-1745.
69. Rosenblatt J.A.I., Vasir B., Katz T., et al. Dendritic cell tumor fusion vaccination in conjunction with autologous transplantation for multiple myeloma. ASH Annual Meet Abstr 2009, 114:783.
70. Lacy M.Q., Mandrekar S., Dispenzieri A., et al. Idiotype-pulsed antigen-presenting cells following autologous transplantation for multiple myeloma may be associated with prolonged survival. Am J Hematol 2009, 84:799-802.
71. Rapoport A.P., Aqui N.A., Stadtmauer E.A., et al. Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma. Blood 2010, 117:788-797.
72. Stadtmauer E.A., Vogl D.T., Luning Prak E., et al. Transfer of influenza vaccine-primed costimulated autologous T cells after stem cell transplantation for multiple myeloma leads to reconstitution of influenza immunity: Results of a randomized clinical trial. Blood 2010, 117:63-71.
73. Rapoport A.P., Stadtmauer E.A., Aqui N., et al. Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. Nat Med 2005, 11:1230-1237.
74. Hodi F.S., O'Day S.J., McDermott D.F., et al. Improved survival with ipilimumab in patients with metastatic melanoma. NEngl J Med 2010, 363:711-723.
75. Ozao-Choy J., Carvajal R.D., Hamid O. Ipilimumab for metastatic melanoma. Drugs Today (Barc) 2012, 48:381-393.
76. Lipson E.J., Drake C.G. Ipilimumab: An anti-CTLA-4 antibody for metastatic melanoma. Clin Cancer Res 2011, 17:6958-6962.
77. Karan D., Van Veldhuizen P. Combination immunotherapy with prostate GVAX and ipilimumab: Safety and toxicity. Immunotherapy 2012, 4:577-580.
78. Keir M.E., Butte M.J., Freeman G.J., Sharpe A.H. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008, 26:677-704.
79. Keir M.E., Francisco L.M., Sharpe A.H. PD-1 and its ligands in T-cell immunity. Curr Opin Immunol 2007, 19:309-314.
80. Rosenblatt J., Glotzbecker B., Mills H., et al. PD-1 blockade by CT-011, anti-PD-1 antibody, enhances exvivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine. JImmunother 2011, 34:409-418.
81. Rezaei N., Mahmoudi E., Aghamohammadi A., et al. X-linked lymphoproliferative syndrome: A genetic condition typified by the triad of infection, immunodeficiency and lymphoma. Br J Haematol 2011, 152:13-30.
82. Biron C.A., Byron K.S., Sullivan J.L. Severe herpesvirus infections in an adolescent without natural killer cells. NEngl J Med 1989, 320:1731-1735.
83. Kim S., Poursine-Laurent J., Truscott S.M., et al. Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature 2005, 436:709-713.
84. Yawata M., Yawata N., Draghi M., et al. Roles for HLA and KIR polymorphisms in natural killer cell repertoire selection and modulation of effector function. JExp Med 2006, 203:633-645.
85. Porrata L., Litzow M., Tefferi A., et al. Early lymphocyte recovery is a predictive factor for prolonged survival after autologous hematopoietic stem cell transplantation for acute myelogenous leukemia. Leukemia 2002, 16:1311-1318.
86. Leung W., Handgretinger R., Iyengar R., et al. Inhibitory KIR-HLA receptor-ligand mismatch in autologous haematopoietic stem cell transplantation for solid tumour and lymphoma. Br J Cancer 2007, 97:539-542.
87. Tarek N., Le Luduec J.B., Gallagher M.M., et al. Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment. JClin Invest 2012, 122:3260-3270.
88. Kohrt H.E., Houot R., Goldstein M.J., et al. CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. Blood 2011, 117:2423-2432.
89. Romagne F., Andre P., Spee P., et al. Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. Blood 2009, 114:2667-2677.
90. Godfrey J., Benson D.M. The role of natural killer cells in immunity against multiple myeloma. Leuk Lymph 2012, 53:1666-1676.
91. Ruggeri L., Capanni M., Casucci M., et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 1999, 94:333-339.
92. Yu J., Venstrom J.M., Liu X.R., et al. Breaking tolerance to self, circulating natural killer cells expressing inhibitory KIR for non-self HLA exhibit effector function after T cell-depleted allogeneic hematopoietic cell transplantation. Blood 2009, 113:3875-3884.
93. Hsu K., Gooley T., Malkki M., et al. KIR ligands and prediction of relapse after unrelated donor hematopoietic cell transplantation for hematologic malignancy. Biol Blood Marrow Transplant 2006, 12:828-836.
94. Cooley S., Trachtenberg E., Bergemann T., et al. Donors with group B haplotypes improve relapse-free survival after unrelated hemaotpoietic transplantation for acute myeloid leukemia. Blood 2009, 113:726-732.
95. Venstrom J., Gooley T., Spellman S., et al. Donor activating KIR3DS1 is associated with decreased acute GvHD in unrelated allogeneic hematopoietic stem cell transplantation. Blood 2010, 115:3162-3165.
96. Chewning J., Gudme C., Hsu K., et al. KIR2DS1-positive NK cells mediate alloresponse against the C2 HLA-KIR ligand group invitro. JImmunol 2007, 179:854-868.
97. Venstrom J.M., Pittari G., Gooley T.A., et al. HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1. NEngl J Med 2012, 367:805-816.